Elisabeth Claire Evjenth

Ms. Elisabeth Claire Evjenth


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SGSonia Gavasso
Sonia Gavasso
TKTorbjørn Kråkenes
Torbjørn Kråkenes
HOHåkon Olsen
Håkon Olsen
EEElisabeth Claire Evjenth
Elisabeth Claire Evjenth
MYMarie Ytterdal
Marie Ytterdal
CKChristopher Elnan Kvistad
Christopher Elnan Kvistad
In multiple sclerosis (MS), there is a great need for treatment with the ability to suppress compartmentalized inflammation within the central nervous system (CNS) and to promote remyelination and regeneration. Mesenchymal stem cells (MSCs) represent a promising therapeutic option, as they have been shown to migrate to the site of CNS injury and exert neuroprotective properties, including immunomodulation, neurotrophic factor secretion, and endogenous neural stem cell stimulation. This review summarizes the current understanding of the underlying neuroprotective mechanisms and discusses the translation of MSC transplantation and their derivatives from pre-clinical demyelinating models to clinical trials with MS patients.

Verified
Journal Article
Open access
PDF file
TKTorbjørn Kråkenes
Torbjørn Kråkenes
CSCasper Eugen Sandvik
Casper Eugen Sandvik
MYMarie Ytterdal
Marie Ytterdal
SGSonia Gavasso
Sonia Gavasso
EEElisabeth Claire Evjenth
Elisabeth Claire Evjenth
CKChristopher Elnan Kvistad
Christopher Elnan Kvistad
Although treatment for multiple sclerosis (MS) has undergone a revolution in the last decades, at least two important barriers remain: alleviation of innate inflammation driving disease progression and promotion of remyelination and neural regeneration. Mesenchymal stem cells (MSCs) possess immunomodulatory properties and promote remyelination in murine MS models. The main therapeutic mechanism has, however, been attributed to their potent paracrine capacity, and not to in vivo tissue implantation. Studies have demonstrated that exosomes released as part of the cells’ secretome effectively encapsulate the beneficial properties of MSCs. These membrane-enclosed nanoparticles contain a variety of proteins and nucleic acids and serve as mediators of intercellular communication. In vitro studies have demonstrated that exosomes from MSCs modulate activated microglia from an inflammatory to an anti-inflammatory phenotype and thereby dampen the innate inflammation. Rodent studies have also demonstrated potent immunomodulation and remyelination with improved outcomes following exosome administration. Thus, exosomes from MSCs may represent a potential cell-free treatment modality to prevent disease progression and promote remyelination in MS. In this narrative review, we summarize the current knowledge of exosomes from MSCs as a potential treatment for MS and discuss the remaining issues before successful translation into clinical trials.